Amolyt Pharma, a France-based developer of treatments for endocrine diseases, completed an $80m series B round yesterday that included pharmaceutical firm Novo, hospital operator Mass General Brigham and insurance firm Sham.
Sectoral Asset Management and Andera Partners co-led the round, which also featured Atem Capital, Kurma Partners, LSP, Bpifrance’s Innobio 2 vehicle, Orbimed, Eurazeo, Pontifax and Credit Agricole Creation.
Novo, Mass General Brigham and Sham invested through Novo Ventures, Mass General Brigham Ventures and Sham Innovation Santé/Turenne Capital respectively.
Amolyt is developing therapeutic peptides to treat diseases of the endocrine system and related illnesses. It will use the funding to advance its product pipeline, which includes potential therapeutics for hypoparathyroidism and acromegaly – both conditions affecting the pituitary gland.
Before it rebranded from Alizé Pharma 3, Amolyt raised $75m in a mid-2019 series A round led by LSP that also featured Novo Ventures, Sham Innovation Santé, consulting firm TAB Consulting, Orbimed, Pontifax, Crédit Agricole Creation, Partners Innovation Fund and Kurma Partners.
The company had previously secured at least $6m across multiple rounds, from investors including Sham Innovation Santé, Crédit Agricole Creation, Octalfa, Rhône-Alpes Création, TAB Consulting and diversified holding company CEMA.
Thierry Abribat, Amolyt’s founder and chief executive, said: “We are very pleased to expand our high-quality syndicate with the addition of these new North American and European investors and we are highly appreciative of the continued support from our existing investors.
“This financing will give us the opportunity to further pursue our mission of building a leading rare endocrine and related disease company, and we will continue to work to introduce new and potentially life-changing therapeutics to patients globally.”
